NCT04822350 2026-04-02
AVENANCE
Pfizer
Completed
Clinical Trials
36 trialsNCT05419362 2025-12-16
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Genome & Company
Phase 2 Completed
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT05431777 2025-04-01
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05650164 2025-03-28
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02576574 2025-01-31
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
Phase 3 Completed
NCT04682587 2025-01-03
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
Completed
NCT04393753 2024-05-08
MERKLIN2
4SC AG
Phase 2 Completed
NCT03558139 2024-04-01
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
Phase 1 Completed
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT03409458 2023-11-18
PAVE-1
Promontory Therapeutics Inc.
Phase 1/2 Completed
NCT03941262 2023-11-13
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
Phase 1 Completed
NCT04601402 2023-08-08
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
Phase 1 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT04065555 2022-07-29
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT03717155 2022-06-06
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT03270176 2022-06-01
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Debiopharm International SA
Phase 1 Completed
NCT03268057 2022-05-02
CLASSICAL-Lung
Vaccinex Inc.
Phase 1/2 Completed
NCT02923466 2022-04-27
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
Vyriad, Inc.
Phase 1 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01772004 2021-12-20
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
Phase 1 Completed
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT02222922 2020-12-17
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT03704467 2020-11-13
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
EMD Serono
Phase 1 Completed
NCT01943461 2020-09-30
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03289533 2020-09-04
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
Phase 1 Completed
NCT02395172 2020-08-03
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
EMD Serono
Phase 3 Completed
NCT03258398 2019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Effector Therapeutics
Phase 2 Completed